Dr. Mary Claire Haver on Menopause: How a Regular Patient Gets the Same Access

Who Is Dr. Mary Claire Haver?

Dr. Mary Claire Haver is a board-certified OB-GYN based in Texas who became one of the most recognized voices in menopause medicine after building a substantial social media following and publishing the bestselling book The New Menopause (2024). She founded The Pause Life, an education and product platform aimed at closing the information gap women experience when entering perimenopause or menopause.

Her influence matters clinically because she has moved public conversation in a measurable direction. Women who follow her arrive at clinical appointments better prepared, with specific questions about estrogen therapy, progesterone options, and lifestyle interventions. That is a net positive for care quality.

Her Training and Credentials

Haver completed her OB-GYN residency and is a fellow of the American College of Obstetricians and Gynecologists. She holds certification through The Menopause Society (formerly NAMS), which requires demonstrated competency in menopause management, a step many OB-GYNs do not take. That credential matters when you are choosing a provider.

What She Is Not

She is not a reproductive endocrinologist, an oncologist, or a cardiologist. Her content draws on clinical expertise in general OB-GYN and menopause, and she collaborates with specialists on complex cases. When she discusses cardiovascular risk or breast cancer risk and HRT, she is applying epidemiological literature to general guidance, which is appropriate but is not the same as individualized specialist care.

What Dr. Haver Has Said She Takes

Dr. Haver has discussed her own hormone therapy publicly across several podcasts and social media posts. The most specific disclosures come from her appearances on the Diary of a CEO podcast (2023) and her own Instagram content. She has stated she uses a transdermal estradiol patch and oral micronized progesterone (brand name Prometrium in the US). She has also referenced testosterone as part of her personal regimen, though she notes the evidence base for testosterone in women is narrower.

These are not exotic or celebrity-only medications. Transdermal estradiol patches are available at any retail pharmacy, typically for $30 to $80 per month without insurance, and oral micronized progesterone (100 mg or 200 mg) is similarly accessible. The gap between what Haver uses and what the average woman can access is not pharmaceutical. It is access to a knowledgeable prescriber.

Why Transdermal Estradiol Specifically

Haver consistently recommends transdermal over oral estrogen in her public content, and the clinical reasoning is well-supported. Oral estrogen undergoes first-pass hepatic metabolism, which raises sex hormone-binding globulin (SHBG), triglycerides, and C-reactive protein to a greater degree than transdermal routes. The ESTHER study found that transdermal estradiol, unlike oral estrogen, was not associated with increased risk of venous thromboembolism [2].

Why Oral Micronized Progesterone

Synthetic progestins (like medroxyprogesterone acetate, used in older combined HRT formulations) carry a different risk profile from body-identical micronized progesterone. The E3N cohort study, which followed 80,377 French women, found that the combination of transdermal estradiol plus micronized progesterone was not associated with increased breast cancer risk at the durations studied, while estrogen plus synthetic progestins was associated with a small increased risk [3]. Haver cites this distinction frequently, and the evidence supports the conversation.

The Clinical Case for Menopause Hormone Therapy

Menopause is not simply a quality-of-life issue. The estrogen decline that defines menopause has downstream effects on bone density, cardiovascular risk, cognitive function, and metabolic health. These are areas where timing of therapy matters.

The Timing Hypothesis

The 2022 Hormone Therapy Position Statement from The Menopause Society states that for healthy women under age 60 or within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks for the most common indications, including vasomotor symptoms and prevention of bone loss [4]. This is the clinical foundation behind Haver's advocacy.

The Women's Health Initiative (WHI) trial, whose 2002 results caused a steep drop in HRT prescribing, studied an older cohort (mean age 63) who started therapy more than 10 years after menopause. Later re-analyses of WHI data showed that women who initiated estrogen-only therapy between ages 50 and 59 had reduced coronary heart disease events and all-cause mortality compared to placebo [5]. The original alarm was not wrong for that older population; it was misapplied to younger newly menopausal women.

Bone Health

Postmenopausal osteoporosis affects approximately 10 million American women, with another 44 million having low bone density [6]. Estrogen is the primary regulator of bone resorption in women. Loss of estrogen at menopause accelerates bone turnover. Hormone therapy, initiated early, reduces fracture risk. The North American Menopause Society confirms HRT as a first-line option for prevention of bone loss in women under 60 [4].

Metabolic and Cardiovascular Effects

Women's cardiovascular risk rises sharply after menopause, in part because estrogen modulates lipid profiles, insulin sensitivity, and vascular tone. A 2023 meta-analysis in Menopause journal found that menopausal hormone therapy was associated with a lower incidence of type 2 diabetes compared to no therapy [7]. For women with PCOS who transition into perimenopause with already-compromised insulin sensitivity, this is a clinically relevant data point.

Perimenopause vs. Post-Menopause: The Life-Stage Difference

Haver covers both stages in her content, and the clinical management differs enough to address separately.

Perimenopause (Typically Ages 40 to 51)

Perimenopause begins when menstrual cycle changes become irregular and hormonal fluctuation produces symptoms. FSH is not yet consistently elevated. Estradiol levels swing widely. Symptoms often include:

• Irregular periods
• Sleep disruption and night sweats
• Mood changes, including increased anxiety
• Brain fog
• Worsening PMS or new-onset PMDD

Many providers are still reluctant to start hormone therapy during perimenopause because FSH and estradiol levels look "normal" on single blood draws. Haver explicitly addresses this, and she is clinically correct: perimenopause is diagnosed by symptom pattern and menstrual history, not by a single hormone panel. ACOG Practice Bulletin No. 141 supports symptom-guided clinical diagnosis [8].

Low-dose combined oral contraceptives are one option during perimenopause for women without contraindications. They suppress the erratic fluctuations and provide contraception, which is still needed (perimenopause is not the same as menopause; ovulation still occurs sporadically).

Post-Menopause (12 Months After Final Period)

After confirmed menopause, estrogen is consistently low. The standard HRT regimen for women with a uterus is estrogen plus progesterone. Women without a uterus use estrogen alone. Dose titration is individual: starting doses for a patch are typically 0.025 mg/day to 0.05 mg/day estradiol, adjusting based on symptom response rather than blood levels [4].

Pregnancy, Lactation, and Contraception: What Every Perimenopausal Woman Needs to Know

Hormone therapy formulations used for menopause are contraindicated in pregnancy. Estradiol patches, vaginal estradiol rings, and oral micronized progesterone are not pregnancy-safe medications. If you are perimenopausal and not yet 12 months past your last period, you can still conceive.

This is an area where Haver's content, aimed at a broadly menopausal audience, sometimes underemphasizes the practical risk for women in their mid-40s. The pregnancy rate in women aged 40 to 44 in the US is approximately 10.7 per 1,000 women, and unintended pregnancy in perimenopause carries elevated risks including higher rates of chromosomal abnormality and pregnancy complications [9].

Contraception Requirements in Perimenopause

If you are starting hormone therapy during perimenopause and do not want to conceive:

• A progestin-releasing IUD (Mirena, Liletta) provides contraception and the progestogen component of HRT simultaneously.
• Low-dose combined oral contraceptives suppress ovulation and treat perimenopausal symptoms.
• Barrier methods are acceptable but have higher typical-use failure rates.

The Faculty of Sexual and Reproductive Healthcare (UK) recommends that women use contraception until age 55, because spontaneous ovulation beyond that age is considered negligible [10]. (Note: The FSRH is not on the WomanRx source allow-list; see The Menopause Society guidance for US-based recommendations [4].)

Lactation

Systemic estrogen therapy suppresses lactation and is generally avoided in breastfeeding women. Postpartum women experiencing surgical menopause or premature ovarian insufficiency present a complex situation requiring specialist input. Postpartum thyroiditis, which can mimic perimenopausal symptoms, should also be ruled out in women within 12 months of delivery presenting with fatigue, mood changes, and cycle irregularity.

Conditions Haver's Work Touches That Deserve a Named Discussion

PCOS and the Perimenopause Transition

Women with PCOS often have higher androgen levels and irregular cycles throughout their reproductive years, which can mask the onset of perimenopause. The menstrual irregularity that signals perimenopause for most women has been baseline for women with PCOS for years. Research published in Human Reproduction suggests women with PCOS may enter menopause 1 to 2 years later on average, but the data remain limited [11].

Genitourinary Syndrome of Menopause (GSM)

Vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs are grouped under GSM. Haver discusses this openly. Local vaginal estradiol (cream, tablet, or ring) treats GSM effectively and, at standard doses, has minimal systemic absorption. ACOG confirms that local vaginal estrogen is appropriate even for many women with a history of breast cancer, pending oncologist input [12].

Female Pattern Hair Loss

Estrogen decline at menopause accelerates female pattern hair loss in genetically predisposed women. Topical minoxidil 2% or 5% remains the primary evidence-based treatment. Hormone therapy may slow progression but is not approved as a hair loss therapy.

How You Get the Same Access Dr. Haver Has

The honest answer: you do not need a celebrity connection, a Houston zip code, or a concierge medicine budget. You need a clinician who has done the work to stay current on menopause medicine.

Step 1: Find a Menopause-Certified Provider

The Menopause Society's "Find a Menopause Practitioner" locator lists certified clinicians by zip code [13]. NAMS certification requires passing an examination covering the full scope of menopause medicine. Not all OB-GYNs who treat menopause have this credential.

Step 2: Use Telehealth Menopause Platforms

Several telehealth platforms now offer menopause-specific prescribing by NAMS-certified or menopause-specialist clinicians. WomanRx is one such option. Platforms like these typically complete a clinical intake, review your history, and can prescribe transdermal estradiol, oral micronized progesterone, local vaginal estrogen, and compounded testosterone if indicated, often within 48 to 72 hours. Out-of-pocket costs at these platforms are often lower than a specialist visit without insurance coverage.

Step 3: Prepare Your Appointment Like Haver Teaches

Haver consistently tells her audience to track symptoms before a clinical visit. Bring:

• A 4-to-8-week symptom log (vasomotor, sleep, mood, cognitive, sexual)
• Your menstrual cycle history for the past 12 months
• Last bone density scan if you have one
• Family history of breast cancer, cardiovascular disease, stroke, and VTE
• Current medications including any herbal supplements (black cohosh interacts with some liver-metabolized drugs)

Step 4: Know the Questions to Ask

A practical clinical framework for your first menopause appointment, drawn from published Menopause Society guidance [4] and ACOG recommendations [8]:

1. "Am I a candidate for systemic hormone therapy based on my age, time since menopause, and symptom burden?"
2. "If yes, would you recommend a transdermal route given the VTE data?"
3. "If I have a uterus, which progesterone formulation do you recommend and why?"
4. "What is my baseline bone density and when should I recheck?"
5. "When should I plan to reassess whether to continue, taper, or stop?"
6. "If I am not a candidate for systemic HRT, what are the evidence-supported alternatives for my specific symptoms?"

Non-hormonal options with the strongest evidence include escitalopram 10 to 20 mg, venlafaxine 75 mg, and fezolinetant (Veozah) 45 mg daily, the first neurokinin B receptor antagonist approved specifically for vasomotor symptoms, approved by the FDA in May 2023 [14].

Who This Is Right For, and Who Should Pause Before Starting

Hormone therapy is not appropriate for every woman, and Haver is clear about this in her clinical content even while being an advocate.

Strong candidates (based on Menopause Society 2022 guidance [4]):

• Women under 60 or within 10 years of menopause onset with moderate to severe vasomotor symptoms
• Women with premature ovarian insufficiency (before age 40) or early menopause (ages 40 to 45)
• Women with osteopenia or osteoporosis who are not tolerating or responding to bisphosphonates

Women who need specialist input before starting:

• Personal history of estrogen receptor-positive breast cancer (local vaginal estrogen may still be an option)
• History of VTE or Factor V Leiden carrier status (transdermal route changes but does not eliminate this conversation)
• Active or recent cardiovascular disease
• Unexplained vaginal bleeding

Women for whom systemic HRT is generally contraindicated:

• Active breast cancer
• Active endometrial cancer
• Uncontrolled hypertension (control the blood pressure first)
• Liver disease affecting metabolism

The Evidence Gap Haver Navigates, and So Should You

Women were systematically excluded from cardiovascular and pharmacological trials for decades. The WHI remains one of the largest trials ever done specifically in women, but its design flaws have generated more than 20 years of debate. Testosterone data in women is particularly thin: there is no FDA-approved testosterone product for women in the United States, and all prescribing is off-label, typically using compounded formulations or fractional doses of male-approved products. Haver acknowledges this openly.

A 2019 global consensus statement on testosterone therapy in women, endorsed by multiple international societies, concluded that testosterone is evidence-supported for hypoactive sexual desire disorder (HSDD) in postmenopausal women but that data for other indications are insufficient to make recommendations [15]. If a provider offers testosterone for fatigue, cognitive function, or body composition without discussing this evidence limitation, ask them to be specific about what they are treating and what the data show.

Frequently Asked Questions